Dr. Kinlaw is a biochemist and molecular plant geneticist who oversees Zea’s drug discovery researcher partnerships and directs Zea’s partners that utilize Lighthouse Platform Technology. As Chief Science Officer, Dr. Kinlaw also drives the company’s earliest evaluation of drug candidates that pioneer new technologies and advance medical research across borders.

Before joining Zea, Dr. Kinlaw worked for the Danforth Plant Science Center as their Director of Innovation Commercialization, bridging plant science discoveries to the marketplace for commercial solutions in agriculture.

Prior, she has held early leadership roles in several early-stage companies, notably TerViva, a company dedicated to commercializing an environmentally friendly tree crop for plant-based protein.  In addition, Dr. Kinlaw has advised more than a hundred early-stage companies in agriculture and renewable energy in developing commercial strategies. She holds a Ph.D. in biochemistry and an MBA from UC Berkeley Haas school of management.

Dr. Kinlaw is passionate about unlocking access to new drug therapies in developed economies and those left out of current biotechnology advances.

‍